FDA
-
-
-
-
-
-
-
Agios receives European approval for PYRUKYND to treat thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $39 at Truist Securities
-
-
-
-
-
-
-
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
-
-
-
-
-
-
-
Agios reports mixed results from sickle cell disease drug trial
-
-
-
-
-
-
-
Goldman Sachs on Agios Pharma (AGIO): 'we see a favorable risk-benefit profile'
-
-
-
-
-
-
-
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

